Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Endo Unit Shutdown Could Strand Incontinence Treatment Praised By FDA Panel

This article was originally published in The Gray Sheet

Executive Summary

Endo International plans to shutter its Astora Women's Health business unit – formerly part of American Medical Systems – this month due to ongoing legal concerns tied to the company’s vaginal mesh products. What’s unclear is what this means for the company’s investigational fecal incontinence treatment, which received unanimous support from an FDA advisory panel just days before the shutdown was announced.


Related Content

AMS: Pelvic Mesh Plaintiffs Enticed
TOPAS Fecal Incontinence Device Gets Unanimous Support For Approval At FDA Panel
PMA Mandate Set For Pelvic Organ Prolapse Transvaginal Mesh
Medtech Solutions For The "Other" Incontinence
Boston Sci Ups Urology Focus With $1.6 Billion AMS Deal
Endo Boosts Urology Device Presence With $2.9 Billion AMS Bid


Related Companies